In this study, we demonstrate that the 3-bromo-isoxazoline derivative AXP-3019 is able to inhibit the glycolytic enzyme GAPDH resulting in inhibition of cell proliferation and blockage of tumour-mass growth in a mouse model of human pancreatic adenocarcinoma. Here, GAPDH is linked to neoplasm.